Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report
Open Access
- 1 March 2014
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (3) , 414-418
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine TumorsChest, 2013
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2011
- Neuroendocrine tumor epidemiologyCancer, 2008
- Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine TumorsClinical Cancer Research, 2007
- Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients☆European Journal of Cardio-Thoracic Surgery, 2007
- Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapyLung Cancer, 2004
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Experience in treatment of metastatic pulmonary carcinoid tumorsAnnals of Oncology, 2001
- Pulmonary CarcinoidChest, 2001
- Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.1979